The F-BAR protein CIP4 in WAS-dependent thrombocytopenia

WAS依赖性血小板减少症中的F-BAR蛋白CIP4

基本信息

  • 批准号:
    8322103
  • 负责人:
  • 金额:
    $ 19.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-08-20 至 2014-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Platelets play a central role in cardiovascular, stroke, and bleeding disease through their quantity, activation, and interaction with the inflammatory and vascular systems. The Wiskott -Aldrich syndrome (WAS) is an X- linked disorder characterized by thrombocytopenia, immunodeficiency, eczema and an increased risk of lymphoma and autoimmunity. The affected gene encodes the cytoskeletal protein, WASP. Through the RhoGTPase, Cdc42, WASp undergoes conformational change that leads to actin polymerization. How WASp results in thrombocytopenia, the most common manifestation of WAS, remains unknown. Cdc42, Src kinases, membrane phospholipids, and SH3 domains control WASP function. Our lab has discovered a new regulator of WASP, CIP4 (Cdc42 interacting protein 4), in a yeast two hybrid screen with the Src kinase Lyn as bait. CIP4 is a member of the F-BAR family of proteins, which remodel the plasma membrane and promote actin polymerization. To determine CIP4's function, we created a CIP4-null mouse. We found that CIP4-/- mice display thrombocytopenia, similar to that observed in WASP-/- mice. The mechanism for thrombocytopenia in WAS is not known. Some studies demonstrate an autoimmune basis; others a defect in proplatelet production. Because our mice do not display signs of autoimmune disease, we favor the hypothesis ("defective proplatelet formation hypothesis") that CIP4-WASP forms a signaling pathway that promotes platelet production and that a deficiency of either CIP4 or WASP perturbs actin polymerization in megakaryocytes, which results in defective proplatelet formation. An alternative "immune destruction hypothesis" states that a defect in this CIP4-WASP pathway promotes autoimmunity and immune-mediated destruction of platelets. We propose to address these hypotheses through the following two specific aims: 1) the defective proplatelet hypothesis by culturing megakaryocyte precursors and megakaryocytes from wild-type, CIP4-/-, WASP-/-, and CIP4-/-WASP-/- mice and analyzing their proplatelet formation. We will use these unique mice strains to analyze proplatelet formation, the interaction of CIP4 with microtubules in megakaryocytes, and ultrastructural features of platelets; and 2) Test the immune destruction hypothesis by labeling platelets and measuring their clearance rates in wild-type, CIP4-/-, WASP-/-, and CIP4-/-WASP-/- mice and measuring their T, B, and NK cell functions. We will use these unique mice strains to measure platelet survival and to correlate with altered immune function.
描述(由申请人提供):血小板通过其数量、激活以及与炎症和血管系统的相互作用,在心血管、中风和出血性疾病中发挥核心作用。Wiskott - aldrich综合征(WAS)是一种以血小板减少、免疫缺陷、湿疹以及淋巴瘤和自身免疫风险增加为特征的X连锁疾病。受影响的基因编码细胞骨架蛋白WASP。通过RhoGTPase Cdc42, WASp发生构象变化,导致肌动蛋白聚合。WASp如何导致血小板减少症(WAS最常见的表现)仍不清楚。Cdc42、Src激酶、膜磷脂和SH3结构域控制WASP的功能。本实验室以Src激酶Lyn为诱饵,在酵母双杂交筛选中发现了一个新的WASP调控因子CIP4 (Cdc42相互作用蛋白4)。CIP4是F-BAR蛋白家族的一员,它重塑质膜并促进肌动蛋白聚合。为了确定CIP4的功能,我们创建了一个CIP4为空的鼠标。我们发现CIP4-/-小鼠表现出血小板减少,与WASP-/-小鼠相似。WAS患者血小板减少的机制尚不清楚。一些研究证实了自身免疫的基础;另一些则是血小板生成缺陷。由于我们的小鼠没有表现出自身免疫性疾病的迹象,我们支持CIP4-WASP形成促进血小板产生的信号通路的假设(“缺陷血小板形成假说”),CIP4或WASP的缺乏会扰乱巨核细胞中的肌动蛋白聚合,从而导致缺陷血小板形成。另一种“免疫破坏假说”认为,CIP4-WASP通路的缺陷促进了自身免疫和免疫介导的血小板破坏。我们提出通过以下两个具体目标来解决这些假设:1)通过培养巨核细胞前体和野生型、CIP4-/-、WASP-/-和CIP4-/- -WASP-/-小鼠的巨核细胞,并分析它们的前血小板形成情况,来验证血小板缺陷假说。我们将利用这些独特的小鼠品系分析血小板前形成、巨核细胞中CIP4与微管的相互作用以及血小板的超微结构特征;2)通过标记血小板并测量其在野生型、CIP4-/-、WASP-/-和CIP4-/- -WASP-/-小鼠中的清除率以及测量其T、B和NK细胞功能来验证免疫破坏假说。我们将使用这些独特的小鼠品系来测量血小板存活率和与免疫功能改变的相关性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Seth Joel Corey其他文献

Seth Joel Corey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Seth Joel Corey', 18)}}的其他基金

Genetic Dissection of Stress Responses in Shwachman-Diamond Syndrome
什瓦赫曼-戴蒙德综合征应激反应的基因剖析
  • 批准号:
    10594366
  • 财政年份:
    2023
  • 资助金额:
    $ 19.51万
  • 项目类别:
Multiscale Modeling of Myelodysplastic Syndromes
骨髓增生异常综合征的多尺度建模
  • 批准号:
    8927960
  • 财政年份:
    2015
  • 资助金额:
    $ 19.51万
  • 项目类别:
Multiscale Modeling of Myelodysplastic Syndromes
骨髓增生异常综合征的多尺度建模
  • 批准号:
    9323833
  • 财政年份:
    2015
  • 资助金额:
    $ 19.51万
  • 项目类别:
Multiscale Modeling of Myelodysplastic Syndromes
骨髓增生异常综合征的多尺度建模
  • 批准号:
    9144830
  • 财政年份:
    2015
  • 资助金额:
    $ 19.51万
  • 项目类别:
Genetic Modifiers for Cancer Stem Cells in Secondary MDS/AML
继发性 MDS/AML 中癌症干细胞的基因修饰
  • 批准号:
    8644088
  • 财政年份:
    2014
  • 资助金额:
    $ 19.51万
  • 项目类别:
Genetic Modifiers for Cancer Stem Cells in Secondary MDS/AML
继发性 MDS/AML 中癌症干细胞的基因修饰
  • 批准号:
    8787717
  • 财政年份:
    2014
  • 资助金额:
    $ 19.51万
  • 项目类别:
The F-BAR protein CIP4 in WAS-dependent thrombocytopenia
WAS依赖性血小板减少症中的F-BAR蛋白CIP4
  • 批准号:
    8202444
  • 财政年份:
    2011
  • 资助金额:
    $ 19.51万
  • 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
  • 批准号:
    7680896
  • 财政年份:
    2006
  • 资助金额:
    $ 19.51万
  • 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
  • 批准号:
    7190561
  • 财政年份:
    2006
  • 资助金额:
    $ 19.51万
  • 项目类别:
Targeted Therapy of Lyn in Myelodysplastic Syndrome
Lyn 治疗骨髓增生异常综合征的靶向治疗
  • 批准号:
    7034786
  • 财政年份:
    2006
  • 资助金额:
    $ 19.51万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 19.51万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了